Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Receivables: 2020-2025

Historic Receivables for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $53.8 million.

  • Xeris Biopharma Holdings' Receivables rose 30.66% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.5 million, marking a year-over-year increase of 20.82%. This contributed to the annual value of $40.4 million for FY2024, which is 3.11% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Receivables is $53.8 million, which was up 1.33% from $53.0 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Receivables high stood at $53.8 million for Q3 2025, and its period low was $13.6 million during Q3 2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median Receivables value was $41.1 million (recorded in 2024), while the average stood at $41.9 million.
  • Its Receivables has fluctuated over the past 5 years, first soared by 153.91% in 2021, then dropped by 10.50% in 2024.
  • Xeris Biopharma Holdings' Receivables (Quarterly) stood at $17.5 million in 2021, then soared by 76.62% to $30.8 million in 2022, then grew by 27.14% to $39.2 million in 2023, then grew by 3.11% to $40.4 million in 2024, then spiked by 30.66% to $53.8 million in 2025.
  • Its last three reported values are $53.8 million in Q3 2025, $53.0 million for Q2 2025, and $46.3 million during Q1 2025.